2016 is expected to be a big year for first-time generics, with an estimated $20 billion targeted for going generic. https://lnkd.in/ba_Mqp7
lab.express-scripts.com
With several name brand drugs falling off patent, new biosimilars potentially gaining approval, and new treatments for cancer, diabetes and hepatitis C, 2016 is shaping up to be a blockbuster year for drugs to gain approval from the U.S. Food &...
No comments:
Post a Comment